GSK Pediarix approval
This article was originally published in Pharmaceutical Approvals Monthly
GlaxoSmithKline's Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), inactivated poliovirus) vaccine clears FDA Dec. 13 for administration to infants at 2, 4 and 6 months. Labeling contains a warning that "administration of Pediarix is associated with higher rates of fever relative to separately administered vaccines." GSK has Phase IV commitments for fever and seizure risk. The firm expects the Feb. 25-26 Advisory Committee on Immunization Practices to make a coverage recommendation for Pediarix. The combination vaccine is priced at slight premium to separate vaccine component
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.